Navigation Links
Boehringer Ingelheim Announces Interim Results Evaluating Virologic Response Rates in HCV/HIV Co-Infected Patients Treated with Faldaprevir
Date:3/4/2013

hibitor that has shown the potential to eliminate interferon from HCV treatment when combined in a regimen with faldaprevir and RBV. Phase 2 trials of this interferon-free regimen have been completed and Phase 3 HCVerso™ trials investigating this regimen are now underway.

Faldaprevir and BI 207127 are investigational compounds and not approved by the FDA. Their safety and efficacy have not been established.

Hepatitis C is a blood-born infectious disease and a leading cause of chronic liver disease, transplant and failure that affects as many as 150 million people globally. In the United States, an estimated 4.1 million Americans have been infected with HCV, of which approximately 3.2 million have chronic HCV infection. Since 1999 there has been a significant increase in deaths due to chronic HCV, accounting for 15,000 deaths in the United States in 2007.

About Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
2. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
3. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
4. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
5. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
8. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
9. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
10. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
11. Boehringer Ingelheim Announces Equine Research Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 22, 2014 Decision Resources Group finds that by ... to be worth $2 billion (U.S. dollars), increasing at a ... five years (to 2018). This growth comes as ... 2013 and 4.9 percent expected over the next three to ... small but highly competitive. The pharmaceutical market is dominated by ...
(Date:9/22/2014)... YORK , September 22, 2014 ... Market Report on "Global Market Study on Ophthalmic Devices: ... by 2020," the global ophthalmic devices market was valued at USD ... at a CAGR of 6.5% from 2014 to 2020, ... in 2020. Browse the full Global Market Study ...
(Date:9/22/2014)... -- AVT, Inc. (OTC Markets: AVTC) ( www.autoretail.com ), a ... announced today that they are starting production of the ... is designed for placement inside optical shops and Eye ... there are over 20,000 optical stores in America.  ... first automated kiosk dedicated to cleaning and sanitizing eyeglasses ...
Breaking Medicine Technology:Despite Its Limited Size, Chile's Pharmaceutical Market Offers Growing Opportunity for Drug Industry 2Despite Its Limited Size, Chile's Pharmaceutical Market Offers Growing Opportunity for Drug Industry 3Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 2Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 3Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 4Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 5Opticwash Pro Enables Optical Retailers to Generate New Revenues and Customer Traffic through a Unique Eyeglass Cleaning System 2
... MARY, Fla., Jan. 26, 2012   In a pediatric ... caring environment, Middleton Pediatrics is one of the first ... to assess their young patients vision.  This revolutionary vision ... important vision data in one second or less.  ...
... 26, 2012  Aria Diagnostics, a molecular diagnostics company, ... study that examines the accuracy of its non-invasive ... (associated with Down syndrome) and Trisomy 18 (associated ... test, coupled with a proprietary algorithm to assess ...
Cached Medicine Technology:Middleton Pediatrics Now Using Spot to Screen Patients 2Middleton Pediatrics Now Using Spot to Screen Patients 3Aria Announces Publication of Independent Study in the American Journal of Obstetrics & Gynecology Using Aria's Technology 2
(Date:9/22/2014)... have developed a chip capable of simulating a ... system to test the effectiveness of nanoparticles and ... a tumor-microenvironment-on-chip (T-MOC) device, will allow researchers to ... barriers that prevent the targeted delivery of therapeutic ... professor of mechanical engineering., Researchers are trying to ...
(Date:9/22/2014)... Almost three-quarters (74%) of parents are aware of ... one-quarter (28%) have used those online ratings to ... to U-M research published today in Pediatrics ... Mott Children,s Hospital National Poll on Children,s Health, ... of physicians influenced their choices in seeking healthcare ...
(Date:9/22/2014)... 22, 2014 (HealthDay News) -- Metformin, a drug commonly ... low levels of thyroid-stimulating hormone (TSH) among patients with ... researchers cautioned that low TSH levels may be associated ... link was not established in this study. Among ... there were 495 incidences of low levels of thyroid-stimulating ...
(Date:9/22/2014)... 2014 “The Race is On!” for the ... Sunday, October 12, 2014 as it moves to its new ... As the signature fundraising and awareness event for Susan G. ... Phoenix Race for the Cure provides supporters of all ages ... and even sleeping in. , “Moving the Race to ...
(Date:9/22/2014)... A study led by University of North Carolina at ... the accurate diagnosis of people who are experiencing the ... delusions that define the development of severe mental disorders ... early adulthood and affects about 1 in every 100 ... person can be a life compromised, and the burden ...
Breaking Medicine News(10 mins):Health News:New chip promising for tumor-targeting research 2Health News:Online ratings influence parents' choices of physicians for their children 2Health News:Diabetes Drug Metformin May Affect Thyroid in Some Patients 2Health News:22nd Annual Susan G. Komen Phoenix Race for the Cure® 2014 Moves to Downtown Phoenix 2Health News:22nd Annual Susan G. Komen Phoenix Race for the Cure® 2014 Moves to Downtown Phoenix 3Health News:Blood test may help determine who is at risk for psychosis 2
... , , PANAMA CITY, Fla., ... hospital, diligence of staff washing their hands when moving from patient ... The Joint Commission , handwashing failures contribute to ... and cost U.S. hospitals $4 billion to $29 billion annually to ...
... , , MINNEAPOLIS, ... officers, introduced new Board Members and thanked outgoing members for their ... General Counsel, Ltd., was elected as the new Board Chair. The ... , David Fisher, Board ...
... , SAN DIEGO, Sept. 16 ... device company, today announced that its application for premarket approval (PMA) ... approved by the Food and Drug Administration. The Company can now ... , Jim Hitchin, SpectraScience,s, CEO said, "We are pleased ...
... ... supplements at 9th Annual Conference on Protein Expression in Animal Cells (PEACe) in Jackson Hole, ... Fort ... well defined and regulatory friendly cell culture media supplements at the 9th Annual PEACe conference ...
... 16 Prime Staffing, a premier staffing services has achieved ... from The Joint Commission. , , Prime ... national standards addressing how staffing firms determine the qualifications and ... how they monitor staff,s performance. , , ...
... , LONDON, Sept. 16 McGraw-Hill Medical won ... Medical Book Competition awards ceremony, including two category first prize awards ... coveted award went to the ground-breaking Robotic Surgery: Theory and ... , , Speaking about the award, Dr Vivienne ...
Cached Medicine News:Health News:Bay Medical Fights Healthcare-Associated Infections by Improving Hand Hygiene 300% 2Health News:Bay Medical Fights Healthcare-Associated Infections by Improving Hand Hygiene 300% 3Health News:Bay Medical Fights Healthcare-Associated Infections by Improving Hand Hygiene 300% 4Health News:ClearWay Minnesota(SM) Board Approves New Officers 2Health News:SpectraScience Receives FDA Approval for Enhancements to WavSTAT(R) Optical Biopsy System 2Health News:InVitria Cell Culture Product Line to Headline PEACe 2Health News:Prime Staffing Awarded Certification from The Joint Commission 2Health News:McGraw-Hill Medical Wins 2009 BMA Medical Book of the Year Award 2
... with concave seats and large backrests with ... backrests, armrests, and casters and glides. • ... in a variety of environments including: industry, ... care and office. • With reinforced nylon ...
... with concave seats and large backrests with ... backrests, armrests, and casters and glides. • ... in a variety of environments including: industry, ... care and office. • With reinforced nylon ...
... concave seats and large backrests with lumbar ... armrests, and casters and glides. • Choose ... a variety of environments including: industry, education, ... and office. • With reinforced nylon base ...
... chairs with concave seats and large backrests ... seats, backrests, armrests, and casters and glides. ... performance in a variety of environments including: ... health care and office. • With cast ...
Medicine Products: